Print

Vical Incorporated (VICL) Reviews Herpes Simplex Vaccine Progress at 2nd International Conference and Exhibition on Cell & Gene Therapy  
10/24/2013 9:42:26 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

ORLANDO, Fla., Oct. 24, 2013 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced that a review of the company's progress toward clinical testing of its Vaxfectin®-formulated therapeutic vaccine against herpes simplex virus type 2 (HSV-2) will be presented at the 2nd International Conference and Exhibition on Cell & Gene Therapy, held in Orlando, Florida. Published results from preclinical therapeutic vaccine studies demonstrated significant reduction in recurrence of viral lesions and viral shedding in HSV-2 infected guinea pigs. A Phase 1/2 clinical trial of the vaccine is expected to begin in late 2013.

Help employers find you! Check out all the jobs and post your resume.

//-->